Bone and Connective Tissue Cancer Archives - Page 3 of 10 - MPR

Bone and Connective Tissue Cancer

FDA Accepts sNDA for Soft Tissue Sarcoma Tx

The Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for eribulin mesylate (Eisai) for the treatment of patients with inoperable soft tissue sarcoma (leiomyosarcoma and liposarcoma) who have received prior chemotherapy for advanced or metastatic disease.